{"product_id":"sanofi-marketing-mix","title":"Sanofi Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSanofi’s 4P’s reveal a balanced mix: innovative pharmaceutical and vaccine products, value-based and tiered pricing, global omni-channel distribution, and multifaceted promotion blending medical education with digital DTC campaigns—tactics that sustain market leadership and patient trust; the preview only scratches the surface. Get the full, editable Marketing Mix Analysis to unlock detailed strategies, data, and presentation-ready insights for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunology and Inflammation Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi’s Immunology and Inflammation leadership centers on Dupixent (dupilumab), the flagship biologic that by end-2025 covered atopic dermatitis, asthma and chronic obstructive pulmonary disease (COPD), with global 2024 sales ~US$9.6bn and 2025 consensus near US$11bn as indications and adult\/pediatric uptake grew.\u003c\/p\u003e\n\u003cp\u003eHigh efficacy and expanding labels keep Dupixent core to Sanofi’s portfolio; lifecycle management—new formulations, pediatric approvals, and evidence-generation—aims to defend share versus biosimilars and new entrants, preserving margin and patient volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Vaccine Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi remains a global vaccines leader in late 2025, with sales around €7.2bn in Vaccines in 2024 and strong positions in influenza, meningitis, and pediatric combos.\u003c\/p\u003e\n\u003cp\u003eBeyfortus (nirsevimab) drove rapid uptake since its 2023 launch, contributing \u0026gt;€1bn in 2024 sales and materially boosting infant-protection market share.\u003c\/p\u003e\n\u003cp\u003eSanofi is shifting R\u0026amp;D toward mRNA and next-gen recombinant platforms, planning multiple mRNA vaccine trials in 2025 to address seasonal virus drift and future pandemics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Care and Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi Specialty Care targets high-value, low-volume markets—Pompe, Gaucher, hemophilia—driven by Genzyme heritage and enzyme replacement therapies; Nexviazyme (launched 2021) treated ~1,200 patients globally by 2024 and contributed to Sanofi Rare Disease revenue of ~€3.6bn in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Healthcare and Opella\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025 Sanofi spun off Consumer Healthcare into Opella to boost agility and brand focus; the unit targets digestive wellness and allergy relief while keeping global retail reach.\u003c\/p\u003e\n\u003cp\u003eOpella houses Allegra, Dulcolax, Enterogermina and aims double-digit margin expansion; Consumer Healthcare contributed about EUR 5.1bn sales in 2024, guiding Opella toward ~EUR 5.5–6.0bn by 2026.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStandalone Opella launched end-2025\u003c\/li\u003e\n\u003cli\u003eKey brands: Allegra, Dulcolax, Enterogermina\u003c\/li\u003e\n\u003cli\u003eFocus: digestive wellness, allergy relief\u003c\/li\u003e\n\u003cli\u003e2024 sales: ~EUR 5.1bn; 2026 target ~EUR 5.5–6.0bn\u003c\/li\u003e\n\u003cli\u003eChannel: strong global retail presence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative R\u0026amp;D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi has redirected R\u0026amp;D to first- or best-in-class drugs, focusing on oncology, neurology, and immunology; biologicals now dominate investment to secure longer patents and market differentiation.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the late-stage pipeline includes tolebrutinib for multiple sclerosis and several monoclonal antibodies, with R\u0026amp;D spend at €6.8bn in 2024 and late-stage assets representing ~35% of pipeline value.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eShift: biologicals over small molecules\u003c\/li\u003e\n\u003cli\u003eFocus: oncology, neurology, immunology\u003c\/li\u003e\n\u003cli\u003eKey asset: tolebrutinib (MS), late-stage mAbs\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend: €6.8bn (2024)\u003c\/li\u003e\n\u003cli\u003eLate-stage share: ~35% of pipeline value (late‑2025)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi: Dupixent \u0026amp; Vaccines Drive Growth as Opella, Rare Diseases and R\u0026amp;D Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi’s product mix is led by Dupixent (2024 sales ~US$9.6bn; 2025 consensus ~US$11bn), vaccines (~€7.2bn 2024) with Beyfortus \u0026gt;€1bn (2024), Rare Disease ~€3.6bn (2024), Consumer Healthcare\/Opella ~€5.1bn (2024) targeting €5.5–6.0bn by 2026; R\u0026amp;D €6.8bn (2024), late‑stage ~35% pipeline value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDupixent\u003c\/td\u003e\n\u003ctd\u003e~US$9.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccines\u003c\/td\u003e\n\u003ctd\u003e~€7.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeyfortus\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare Disease\u003c\/td\u003e\n\u003ctd\u003e~€3.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpella\u003c\/td\u003e\n\u003ctd\u003e~€5.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Sanofi’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground the analysis for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Sanofi’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, distribution channels, and promotional priorities to speed decision-making and cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi runs ~60 manufacturing sites across Europe, North America and Asia, producing complex biologics and vaccines that contributed €11.2bn in 2024 group sales for vaccines and rare disease units combined. \u003c\/p\u003e\n\u003cp\u003eSince 2021 Sanofi has invested \u0026gt;€1.3bn in Factory of the Future upgrades—digital automation and single‑use bioreactors—cutting batch cycle time ~18% and energy use ~12% per site. \u003c\/p\u003e\n\u003cp\u003eRegionalized plants in EU, US and Singapore shorten lead times, lowering geopolitics-driven stockout risk; inventory days fell from 98 (2020) to 74 (2024). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSanofi uses direct distribution plus third-party logistics and, in the US, partners with wholesalers McKesson and AmerisourceBergen—together they handled roughly 70% of pharma distribution volumes in 2024—ensuring broad hospital and clinic reach.\u003c\/p\u003e\n\u003cp\u003eFor biologics like Dupixent (2024 sales about €9.3bn), Sanofi routes through specialty pharmacies that manage cold chain, infusion scheduling, and patient support programs to maintain adherence and shelf-life.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health and Government Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant share of Sanofi’s vaccines revenue—about 35% of its Vaccines business in 2024 (~€2.1 billion of €6.0 billion total vaccines sales)—flows through national immunization programs and government procurement. Sanofi works with partners like Gavi, the Vaccine Alliance, supplying low-cost doses to 60+ low-income countries under pooled procurement agreements. These institutional channels enable high-volume shipment, lower per-unit prices, and faster global penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and E-commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi sells consumer health products widely through pharmacies, supermarkets, and convenience stores, supporting broad shelf presence for brands like Allegra.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Sanofi is expanding e-commerce and direct-to-patient digital storefronts; online sales for consumer health rose ~22% YoY in 2024, aiding rapid delivery reach.\u003c\/p\u003e\n\u003cp\u003eThis omnichannel mix boosts availability and conversion—physical trust plus fast online fulfillment—driving share growth in OTC categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharmacies\/supermarkets: primary channels\u003c\/li\u003e\n\u003cli\u003e2024 online growth: ~22% YoY\u003c\/li\u003e\n\u003cli\u003eDirect-to-patient stores: growing 2023–25\u003c\/li\u003e\n\u003cli\u003eAllegra: in-store + rapid delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Markets Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSanofi has a deep presence in emerging markets—China, Brazil, and parts of Africa—where 2024 sales from Emerging Markets were about €9.1bn, ~22% of group revenue, helping offset slower growth in Europe and the US.\u003c\/p\u003e\n\u003cp\u003eThe company adapts distribution to local realities, building cold-chain and last-mile networks to reach rural clinics and overcome infrastructure gaps, reducing stockouts and improving access to vaccines and insulin.\u003c\/p\u003e\n\u003cp\u003eGeographic diversity captures growth from expanding middle classes: IMF 2024 GDP growth in Emerging Asia (~4.6%) and Sub-Saharan Africa (~3.5%) and rising healthcare spend support volume growth and pricing flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Emerging Markets sales ≈ €9.1bn, 22% of revenue\u003c\/li\u003e\n\u003cli\u003eFocus: cold-chain, last-mile, local partnerships\u003c\/li\u003e\n\u003cli\u003eMacro tailwinds: Emerging Asia GDP ~4.6% (2024), Sub-Saharan Africa ~3.5% (IMF)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi modernizes 60-site network with €1.3bn+ upgrades—inventory down, EM sales €9.1bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi’s global, regionalized manufacturing (≈60 sites) and \u0026gt;€1.3bn Factory of the Future upgrades cut lead times and energy use; inventory days fell 98→74 (2020–24). Distribution mixes direct, 3PLs, US wholesalers (McKesson\/AmerisourceBergen), specialty pharmacies for biologics, and government channels (35% Vaccines via procurement\/Gavi). Emerging Markets sales €9.1bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e~60\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactory investment\u003c\/td\u003e\n\u003ctd\u003e€1.3bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e74\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging Markets sales\u003c\/td\u003e\n\u003ctd\u003e€9.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSanofi 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact, full Sanofi 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750423343481,"sku":"sanofi-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sanofi-marketing-mix.png?v=1772224850","url":"https:\/\/matrixbcg.com\/products\/sanofi-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}